NUVB Nuvation Bio Inc.
XNYS
4.39
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NUVB
$4.39
—
What changed
Recent filings, trades and movesKey stats
$4.39
- 52-Week Range
- $3.98 – $9.75
- YTD
- -48.83%
- IV Rank (30D)
- 24.15
- Straddle Price
- $1.38
- P/C Vol Ratio
- 1.93
- Market Cap
- $1.5B
- Open
- $4.23
- Day Range
- $4.08 – $4.41
- Volume
- 2,235,343
- Prev Close
- $4.16
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.31 |
| Cost of Equity (CAPM) | 12.09% (VRP-adj) |
| WACC | 11.14% |
| Volatility Risk Premium | +117.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +7.4% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.07 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -59.6% |
| Book / Price | 15.6% |
| Gross Margin (TTM) | 87.9% |
| FCF Margin (TTM) | -53.6% |
| Debt / Equity | 1.23 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $5.39 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $4.62 |
| Bollinger Width / SMA20 | 16.4% (drives anchor stability) |
| Net Debt | $0.1B |
| Market Cap | $1B |
Peers used for multiples: BMY, EXEL, GMAB, JNJ, LLY, MRK, MRNA, RVMD
60-Day Conviction
80%
20-Day Fair Value
≈ by Dec 8, 2026
$4.35
α -0.9%
rank 51%
conviction
61%
40-Day Fair Value
≈ by Jan 6, 2027
$4.51
α +2.9%
rank 60%
conviction
78%
60-Day Fair Value
≈ by Feb 4, 2027
$4.55
α +3.9%
rank 55%
conviction
80%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 40.7× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 20.6× · 5 peers |
| Peer P/B | $5.92 | 18% | median 9.1× · 7 peers |
| Peer P/S | $4.13 | 18% | median 6.7× · 7 peers |
| Market Anchor (SMA50) | $5.39 | 64% | stability 68% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $1.5B
- Employees
- 310
- List Date
- 2021-02-10
- CIK
- 0001811063
- Last Earnings
- Nov 4 after close · −11.4% vs ±20.6% expected
- Headquarters
- New York, NY
- Homepage
- https://www.nuvationbio.com
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -30.92% | 21.78% | 3.18% | -10.81% | -38.93% | -11.14% |
| Feb | 1.93% | -16.64% | -21.77% | 16.88% | -13.22% | 4.97% | -4.64% |
| Mar | -1.14% | 7.57% | -10.27% | 63.23% | -3.30% | -26.54% | 4.92% |
| Apr | 9.71% | -15.27% | -7.47% | -18.97% | 28.57% | -1.33% | -0.79% |
| May | 30.82% | -26.76% | 0.62% | -3.13% | -6.61% | 6.46% | 0.23% |
| Jun | -31.54% | -6.90% | 10.43% | 7.35% | -16.67% | 14.52% | -3.80% |
| Jul | -7.59% | -21.59% | 5.11% | 21.20% | 21.65% | 17.55% | 6.05% |
| Aug | 4.18% | 12.45% | -13.23% | -9.30% | 33.18% | 8.12% | 5.90% |
| Sep | 6.31% | -20.28% | -18.29% | -23.15% | 25.42% | -15.66% | -7.61% |
| Oct | -8.76% | -3.08% | -23.52% | -3.91% | 41.08% | -14.39% | -2.10% |
| Nov | -0.44% | -17.67% | 6.90% | 26.09% | 55.32% | -4.68%* | 10.92% |
| Dec | -2.97% | -3.03% | 13.53% | -10.74% | 13.71% | -- | 2.10% |
| Total | -10.68% | -80.54% | -39.21% | 51.55% | 279.15% | -50.45% | 24.97% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $4.59
SMA 50: $5.34
SMA 200: $5.35
Current: $4.38
EMA 12: $4.52
EMA 26: $4.77
MACD: -0.2490 | Signal: 0.0107
BEARISH
ADX (14): 34.73
TREND
+DI: 13.23
−DI: 31.30
Momentum Oscillators
RSI (14): 38.70
NEUTRAL
Stoch %K: 20.39
Stoch %D: 29.31
Williams %R: -58.88
Volume & Volatility
BB Upper: $4.96
BB Lower: $4.23
NEUTRAL
OBV: 17,239,677
Vol SMA 20: 5,200,915
Vol ROC: -39.47%
ATR: $0.28
True Range: $0.33
HV 20: 65.6%
HV 30: 58.8%
HV 60: 56.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before NUVB’s Nov 4 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers:
- High volatility, with beta of 2.07
- Recent insider selling activity
- Overbought RSI reading at 76.35
Primary Risks:
- Volatility-driven price movements
- Negative sentiment from recent news headlines
Investment Thesis: NUVB is overbought and due for a correction given its high volatility and negative sentiment from recent news headlines.
Recent News Sentiment Impact: The recent news headlines have had a neutral impact on the stock, with mixed sentiments from positive (Veteran Pharma VC Insider Buys 25,000 NUVB Shares) and negative (Insider Sells 200K Shares of Biotech Company Nuvation Bio) news stories.
Technical Analysis
Trend Direction: Short-term: BEARISH (1-4 weeks), Medium-term: NEUTRAL (1-3 months), Long-term: BULLISH (3-12 months)
Support/Resistance Levels: Key price levels include $5.11 (SMA 20) and $4.15 (Bollinger Bands Lower).
Momentum Signals:
- RSI interpretation: OVERBOUGHT (>70)
- MACD signal: BULLISH (0.32 / Signal: 0.15 / Histogram: 0.17)
- Bollinger Bands position: OVERBOUGHT
Volume Analysis: Volume trends are bearish, with a volume rate of change of -2.99%.
News & Sentiment Analysis
Recent Headlines Summary: Recent news headlines have been mixed, with positive sentiment from the Veteran Pharma VC Insider Buys 25,000 NUVB Shares article and negative sentiment from the Insider Sells 200K Shares of Biotech Company Nuvation Bio article.
Sentiment Assessment: Overall sentiment is NEUTRAL, with a mix of positive and negative news stories.
Catalyst Identification: Upcoming earnings information could provide a catalyst for the stock's price movement.
Market Narrative: The recent news headlines have not had a significant impact on the stock's technical signals, which remain bearish in the short-term.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to market (beta >1.2).
Volatility Regime: Current volatility is higher than historical levels.
Options Market Signals: IV rank is low at 5.4%, indicating historically low volatility.
Downside Protection: Support levels include $5.11 (SMA 20) and $4.15 (Bollinger Bands Lower).
Market Context & Positioning
Sector Performance: NUVB's sector performance has been neutral relative to the broader market.
Institutional Activity: Institutional interest is low, with a put/call volume ratio of 0.03.
Correlation Analysis: NUVB's correlation with the market is 0.29, indicating a high degree of independence from market movements.
Relative Valuation: NUVB is positioned within its trading range.
Key Levels & Action Items
Critical Price Levels: Support levels include $5.11 (SMA 20) and $4.15 (Bollinger Bands Lower).
Breakout/Breakdown Levels: A breakout above $6.07 (Upper Bollinger Band) could signal a strong uptrend, while a breakdown below $4.88 (SMA 50) could indicate a further decline.
Time-Sensitive Catalysts: Upcoming earnings information could provide a catalyst for the stock's price movement.
Risk Management: A stop-loss level of $5.15 (EMA 12) could help manage risk, with a position sizing consideration of 1.2 times the initial investment.
Note: The analysis is based on the provided data and should not be considered as personalized investment advice.
Generated
News
All NUVB news →
Management weighed a European milestone and new glioma data ahead of 2027.
Earnings History
12 of 12 under expected move
Avg Expected Move
38.02%
Avg Actual Move
7.00%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-04 | After-Close | 54.32% | 3.09% | 0.06x | Within |
| 2023-08-03 | After-Close | 46.02% | 4.55% | 0.10x | Within |
| 2024-08-05 | After-Close | 40.88% | 6.29% | 0.15x | Within |
| 2024-11-06 | After-Close | 27.56% | 3.15% | 0.11x | Within |
| 2025-05-07 | After-Close | 23.28% | 2.94% | 0.13x | Within |
| 2025-08-07 | After-Close | 13.89% | 1.71% | 0.12x | Within |
| 2025-11-03 | After-Close | 24.18% | 6.58% | 0.27x | Within |
| 2026-01-12 | After-Close | 20.90% | 1.39% | 0.07x | Within |
| 2026-03-02 | After-Close | 143.41% | 25.34% | 0.18x | Within |
| 2026-05-04 | After-Close | 18.71% | 9.52% | 0.51x | Within |
| 2026-08-06 | After-Close | 22.50% | 8.02% | 0.36x | Within |
| 2026-11-04 | After-Close | 20.61% | 11.42% | 0.55x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
NUVB Options Activity & IV Rank
NUVB IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 107.2%
7-DTE IV: 121.2%
Expected Move: $1.38
7-DTE Move: $1.07
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 471
Put Volume: 907
P/C Volume: 1.926
BEARISH
Call OI: 20,750
Put OI: 10,327
P/C OI: 0.498
Total OI: 31,077
ATM Options Pricing
ATM Call: $0.25
ATM Put: $1.12
Call %: 5.7%
Put %: 25.6%
Chain Summary
Chain Volume: 1,378
Chain OI: 31,077
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 26th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
26%
vs own history
GEX tilt
-0.10
OI-weighted, today
Vanna tilt
+0.08
δ-sensitivity to IV
Charm tilt
+0.20
δ-decay vs time
? What is this?
· 6 ATM contracts, 10k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)24.9LowNov 9
IV Rank (30 DTE)24.1LowNov 9
Straddle Price (30 DTE)$1.38Nov 9
Beta Analysis
Risk Metrics
Beta: 1.6955
Alpha: 2.79%
Correlation: 0.2828
R-Squared: 8.0%
Stock Volatility: 82.6%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own NUVB
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $28.0M | #970 of 6285 | +770.9% | 13F | |
| Duquesne Family Office Family office Stanley Druckenmiller | $25.8M | #32 of 86 | 0.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $10.7M | #1527 of 3716 | +668.4% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $7.6M | #1203 of 3138 | +140.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $87K | #3068 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NUVB Institutional Ownership (13F)
Filings for 2026-06-30 · 91 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 355,641,250 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$37.79M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | UBS Group AG Custodian | $36.21M | 95.81% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $503.82K | 1.33% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $437.93K | 1.16% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $351.02K | 0.93% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $186.87K | 0.49% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $104.16K | 0.28% | 2026-09-30 |
5 filers$3.44M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $1.58M | 45.86% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $653.77K | 19.03% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $566.86K | 16.50% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $482.80K | 14.05% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $156.80K | 4.56% | 2026-09-30 |
NUVB Insider Trading (Form 4)
Latest: 2026-08-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Gary Hattersley | CHIEF SCIENTIFIC OFFICER | Mixed Sell −100,000 · Exer +100,000 |
— | $4.48 | -$522.2K | EDGAR |
| 2026-07-17 | Philippe Sauvage | Chief Financial Officer | Exer (M) | +40,000 | $2.17 | $86.8K | EDGAR |
| 2026-06-24 | Philippe Sauvage | Chief Financial Officer | Mixed Exer +47,668 · Sell −47,668 |
— | $4.09 | -$182.9K | EDGAR |
| 2026-06-24 | Stacy Markel | CHIEF PEOPLE OFFICER | Mixed Sell −125,000 · Exer +125,000 |
— | $3.93 | -$523.9K | EDGAR |
| 2026-06-24 | Kerry Wentworth | CHIEF REGULATORY OFFICER | Mixed Exer +63,000 · Sell −63,000 |
— | $4.47 | -$194.6K | EDGAR |
| 2026-06-11 | Robert Mashal | Director | Buy (P) | +25,000 | $4.73 | $118.3K | EDGAR |
| 2026-05-26 | Robert B Bazemore | Director | Grant (A) | +123,397 opt | — | EDGAR | |
| 2026-05-26 | Xiangmin Cui | Director | Grant (A) | +76,923 opt | — | EDGAR | |
| 2026-05-26 | Kathryn E Falberg | Director | Grant (A) | +123,397 opt | — | EDGAR | |
| 2026-05-26 | Xiangmin Cui | Director | Grant (A) | +123,397 opt | — | EDGAR | |
| 2026-05-26 | W Anthony Vernon | Director | Grant (A) | +123,397 opt | — | EDGAR | |
| 2026-05-26 | Robert Mashal | Director | Grant (A) | +123,397 opt | — | EDGAR | |
| 2026-05-26 | Kim D Blickenstaff | Director | Grant (A) | +123,397 opt | — | EDGAR | |
| 2026-04-21 | Kerry Wentworth | CHIEF REGULATORY OFFICER | Mixed Sell −36,750 · Exer +36,750 |
— | $3.97 | -$76.6K | EDGAR |
| 2026-04-21 | Dongfang Liu | CHIEF MEDICAL OFFICER | Mixed Exer +50,000 · Sell −50,000 |
— | $3.48 | -$154.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NUVB Insider Holdings
8 insiders · @ $4.38
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Robert Mashal | Director | 225,000 | $985.5K | $118.3K | 2 | 2026-06-11 |
| 2 | Stacy Markel | CHIEF PEOPLE OFFICER | 122,971 | $538.6K | -$753.2K | 2 | 2026-06-24 |
| 3 | Gary Hattersley | CHIEF SCIENTIFIC OFFICER | 100,000 | $438.0K | -$709.2K | 2 | 2026-08-21 |
| 4 | Colleen Sjogren | Chief Commercial Officer | 84,000 | $367.9K | $0 | 1 | 2026-03-03 |
| 5 | Moses Makunje | SEE REMARKS | 68,137 | $298.4K | $0 | 1 | 2026-03-03 |
| 6 | Philippe Sauvage | Chief Financial Officer | 54,130 | $237.1K | -$286.4K | 3 | 2026-07-17 |
| 7 | Kerry Wentworth | CHIEF REGULATORY OFFICER | 53,000 | $232.1K | -$1.47M | 4 | 2026-06-24 |
| 8 | Dongfang Liu | CHIEF MEDICAL OFFICER | 18,000 | $78.8K | -$251.0K | 2 | 2026-04-21 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NUVB Board & Officers
As of SEC filings through Aug 21, 2026Directors 7
- David Hung · since Feb 10, 2021
- Kathryn E Falberg · since Feb 10, 2021
- Kim D Blickenstaff · since Feb 10, 2021
- Robert B Bazemore · since Feb 10, 2021
- W Anthony Vernon · since Feb 10, 2021
- Robert Mashal · since Jan 8, 2024
- Xiangmin Cui · since Apr 9, 2024
Officers 9
- David Hung · President and CEO · since Feb 10, 2021
- Philippe Sauvage · Chief Financial Officer · since Oct 7, 2024
- Kerry Wentworth · Chief Regulatory Officer · since May 23, 2020
- Gary Hattersley · Chief Scientific Officer · since Feb 10, 2021
- David C. Hanley · Chief Technical Operations · since Jun 1, 2021
- Stacy Markel · Chief People Officer · listed since Mar 2022
- Dongfang Liu · Chief Medical Officer · since Jul 15, 2022
- Colleen Sjogren · Chief Commercial Officer · since Mar 27, 2024
- Moses Makunje · Title: VP, Finance and principal financial and accounting officer. · since Nov 27, 2023
10% owners 1
- David Hung · since Feb 10, 2021
Changes in the last 10 years (89)
| Feb 12, 2025 | The company announced the departure of Junyuan Jerry Wang as CEO, Anheart Therapeutics Ltd. in an SEC filing |
| Oct 7, 2024 | Philippe Sauvage became Chief Financial Officer |
| Apr 9, 2024 | Xiangmin Cui became a director |
| Apr 9, 2024 | Junyuan Jerry Wang became a director |
| Apr 9, 2024 | Junyuan Jerry Wang became CEO, Anheart Therapeutics Ltd. |
| Mar 27, 2024 | Colleen Sjogren became Chief Commercial Officer |
| Jan 8, 2024 | Robert Mashal became a director |
| Dec 11, 2023 | The company announced the departure of Oleg Nodelman from the board in an SEC filing |
| Nov 27, 2023 | Moses Makunje became Title: VP, Finance and principal financial and accounting officer. |
| Nov 9, 2023 | The company announced the departure of Jennifer A. Fox as Chief Financial Officer in an SEC filing |
| Sep 21, 2023 | EcoR1 Venture Opportunity Fund, LP first listed as a director in an SEC filing |
| Sep 21, 2023 | EcoR1 Capital, LLC first listed as a director in an SEC filing |
| Sep 21, 2023 | EcoR1 Capital Fund, L.P. first listed as a director in an SEC filing |
| Sep 21, 2023 | EcoR1 Capital Fund Qualified, L.P. first listed as a director in an SEC filing |
| Sep 21, 2023 | Biotech Opportunity GP, LLC first listed as a director in an SEC filing |
| Jul 15, 2022 | Dongfang Liu became Chief Medical Officer |
| Apr 7, 2022 | Omega Fund V, L.P. reported in an SEC filing no longer being a 10% owner |
| Apr 7, 2022 | Omega Fund V GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Apr 7, 2022 | Omega Fund V GP Manager, Ltd. reported in an SEC filing no longer being a 10% owner |
| Mar 2, 2022 | Stacy Markel listed as Chief People Officer (previously SVP, Human Resources) in SEC filings |
| Dec 17, 2021 | Omega Fund IV GP, L.P. first on file as a 10% owner |
| Nov 30, 2021 | Oleg Nodelman no longer listed as a 10% owner in SEC filings |
| Nov 30, 2021 | EcoR1 Venture Opportunity Fund, LP no longer listed as a 10% owner in SEC filings |
| Nov 30, 2021 | EcoR1 Capital, LLC no longer listed as a 10% owner in SEC filings |
| Nov 30, 2021 | EcoR1 Capital Fund, L.P. no longer listed as a 10% owner in SEC filings |
| Nov 30, 2021 | EcoR1 Capital Fund Qualified, L.P. no longer listed as a 10% owner in SEC filings |
| Nov 30, 2021 | Biotech Opportunity GP, LLC no longer listed as a 10% owner in SEC filings |
| Jun 1, 2021 | David C. Hanley became Chief Technical Operations |
| Feb 26, 2021 | Shalini Sharp reported in an SEC filing no longer being a director |
| Feb 26, 2021 | Graham K Cooper reported in an SEC filing no longer being a director |
| Feb 26, 2021 | Faheem Hasnain reported in an SEC filing no longer being a director |
| Feb 26, 2021 | Daniel Bradbury reported in an SEC filing no longer being a director |
| Feb 12, 2021 | Oleg Nodelman no longer listed as CEO and Chairman of the Board in SEC filings |
| Feb 12, 2021 | Oleg Nodelman first listed as a 10% owner in an SEC filing |
| Feb 12, 2021 | EcoR1 Venture Opportunity Fund, LP no longer listed as a director in SEC filings |
| Feb 12, 2021 | EcoR1 Panacea Holdings, LLC no longer listed as a director in SEC filings |
| Feb 12, 2021 | EcoR1 Capital, LLC no longer listed as a director in SEC filings |
| Feb 12, 2021 | EcoR1 Capital Fund, L.P. no longer listed as a director in SEC filings |
| Feb 12, 2021 | EcoR1 Capital Fund Qualified, L.P. no longer listed as a director in SEC filings |
| Feb 12, 2021 | Biotech Opportunity GP, LLC no longer listed as a director in SEC filings |
| Feb 10, 2021 | W Anthony Vernon became a director |
| Feb 10, 2021 | Thomas Templeman became SVP, Pharmaceutical Ops |
| Feb 10, 2021 | Stacy Markel became SVP, Human Resources |
| Feb 10, 2021 | Sergey Yurasov became Chief Medical Officer |
| Feb 10, 2021 | Robert B Bazemore became a director |
| Feb 10, 2021 | Otello Stampacchia became a 10% owner |
| Feb 10, 2021 | Omega Fund V, L.P. became a 10% owner |
| Feb 10, 2021 | Omega Fund V GP, L.P. became a 10% owner |
| Feb 10, 2021 | Omega Fund V GP Manager, Ltd. became a 10% owner |
| Feb 10, 2021 | Michelle Doig became a director |
| Feb 10, 2021 | Kim D Blickenstaff became a director |
| Feb 10, 2021 | Kathryn E Falberg became a director |
| Feb 10, 2021 | Jennifer A. Fox became Chief Financial Officer |
| Feb 10, 2021 | Gary Hattersley became Chief Scientific Officer |
| Feb 10, 2021 | David Hung became a director |
| Feb 10, 2021 | David Hung became a 10% owner |
| Feb 10, 2021 | David Hung became President and CEO |
| Feb 10, 2021 | Daniel G Welch became a director |
| Feb 10, 2021 | Claudio Nessi became a 10% owner |
| Feb 10, 2021 | Anne-Mari Paster became a 10% owner |
| Jun 30, 2020 | Shalini Sharp became a director |
| Jun 30, 2020 | Scott Platshon became Chief Operating Officer |
| Jun 30, 2020 | Scott Perlen became Chief Financial Officer |
| Jun 30, 2020 | Sarah Marriott became a director |
| Jun 30, 2020 | Sarah Marriott became Secretary |
| Jun 30, 2020 | RCG LV Pearl LLC became a 10% owner |
| Jun 30, 2020 | PA Co-Investment LLC became a 10% owner |
| Jun 30, 2020 | Oleg Nodelman became a director |
| Jun 30, 2020 | Oleg Nodelman became CEO and Chairman of the Board |
| Jun 30, 2020 | Jeffrey M Solomon became a 10% owner |
| Jun 30, 2020 | Graham K Cooper became a director |
| Jun 30, 2020 | Faheem Hasnain became a director |
| Jun 30, 2020 | EcoR1 Venture Opportunity Fund, LP became a director |
| Jun 30, 2020 | EcoR1 Venture Opportunity Fund, LP became a 10% owner |
| Jun 30, 2020 | EcoR1 Panacea Holdings, LLC became a director |
| Jun 30, 2020 | EcoR1 Panacea Holdings, LLC became a 10% owner |
| Jun 30, 2020 | EcoR1 Capital, LLC became a director |
| Jun 30, 2020 | EcoR1 Capital, LLC became a 10% owner |
| Jun 30, 2020 | EcoR1 Capital Fund, L.P. became a director |
| Jun 30, 2020 | EcoR1 Capital Fund, L.P. became a 10% owner |
| Jun 30, 2020 | EcoR1 Capital Fund Qualified, L.P. became a director |
| Jun 30, 2020 | EcoR1 Capital Fund Qualified, L.P. became a 10% owner |
| Jun 30, 2020 | Daniel Bradbury became a director |
| Jun 30, 2020 | Cowen Investments II LLC became a 10% owner |
| Jun 30, 2020 | Cowen Inc. became a 10% owner |
| Jun 30, 2020 | Caroline Stout became Chief Investment Officer |
| Jun 30, 2020 | Biotech Opportunity GP, LLC became a director |
| Jun 30, 2020 | Biotech Opportunity GP, LLC became a 10% owner |
| May 23, 2020 | Kerry Wentworth became Chief Regulatory Officer |
Not reported recently (24)
- Junyuan Jerry Wang · Last reported as a director in an SEC filing dated Nov 13, 2024
- Daniel G Welch · Last reported as a director in an SEC filing dated May 29, 2024
- Biotech Opportunity GP, LLC · Last reported as a director in an SEC filing dated Sep 22, 2023
- EcoR1 Capital, LLC · Last reported as a director in an SEC filing dated Sep 22, 2023
- EcoR1 Venture Opportunity Fund, LP · Last reported as a director in an SEC filing dated Sep 22, 2023
- EcoR1 Capital Fund, L.P. · Last reported as a director in an SEC filing dated Sep 22, 2023
- EcoR1 Capital Fund Qualified, L.P. · Last reported as a director in an SEC filing dated Sep 22, 2023
- Omega Fund IV GP, L.P. · Last reported as a 10% owner in an SEC filing dated Dec 17, 2021
- EcoR1 Panacea Holdings, LLC · Last reported as a 10% owner in an SEC filing dated Apr 13, 2021
- Anne-Mari Paster · Last reported as a 10% owner in an SEC filing dated Feb 12, 2021
- Claudio Nessi · Last reported as a 10% owner in an SEC filing dated Feb 12, 2021
- Michelle Doig · Last reported as a director in an SEC filing dated Feb 12, 2021
- Otello Stampacchia · Last reported as a 10% owner in an SEC filing dated Feb 12, 2021
- Thomas Templeman · Last reported as SVP, Pharmaceutical Ops in an SEC filing dated Feb 12, 2021
- Sergey Yurasov · Last reported as Chief Medical Officer in an SEC filing dated Feb 12, 2021
- Jeffrey M Solomon · Last reported as a 10% owner in an SEC filing dated Jun 30, 2020
- Cowen Inc. · Last reported as a 10% owner in an SEC filing dated Jun 30, 2020
- PA Co-Investment LLC · Last reported as a 10% owner in an SEC filing dated Jun 30, 2020
- RCG LV Pearl LLC · Last reported as a 10% owner in an SEC filing dated Jun 30, 2020
- Cowen Investments II LLC · Last reported as a 10% owner in an SEC filing dated Jun 30, 2020
- Caroline Stout · Last reported as Chief Investment Officer in an SEC filing dated Jun 30, 2020
- Scott Platshon · Last reported as Chief Operating Officer in an SEC filing dated Jun 30, 2020
- Scott Perlen · Last reported as Chief Financial Officer in an SEC filing dated Jun 30, 2020
- Sarah Marriott · Last reported as a director in an SEC filing dated Jun 30, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
NUVB Proposed Insider Sales (Form 144)
Latest: 2026-08-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $696K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
GARY HATTERSLEY (1, $696K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | GARY HATTERSLEY | Officer | 100,000 | $696.0K | 2026-08-19 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-23 | STACY MARKEL | Officer | 125,000 | $720.0K | 2026-06-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-23 | KERRY WENTWORTH | Officer | 63,000 | $362.9K | 2026-06-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-23 | PHILIPPE SAUVAGE | Officer | 47,668 | $274.6K | 2026-06-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-17 | DONGFANG LIU | Officer | 50,000 | $240.5K | 2026-04-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-17 | KERRY WENTWORTH | Officer | 36,750 | $176.8K | 2026-04-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-06 | KERRY WENTWORTH | Officer | 200,000 | $882.0K | 2026-04-06 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-01 | DONGFANG LIU | Officer | 150,000 | $1.17M | 2025-12-01 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-11-26 | DONGFANG LIU | Officer | 10,000 | $80.0K | 2025-11-26 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-11-25 | DONGFANG LIU | Officer | 10,000 | $75.0K | 2025-11-25 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
57 ETFs hold NUVB
25 shown · $178.56M total exposure · 0.04% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $49.8M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.04% | $27.0M | $76.6B | 2026-11-06 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $16.7M | — | 2026-09-30 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.07% | $9.9M | $13.7B | 2026-11-06 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.05% | $8.2M | — | 2026-09-30 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.07% | $7.9M | $11.1B | 2026-11-06 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.03% | $7.7M | — | 2026-08-31 |
| 8 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 1.36% | $6.4M | $466.5M | 2026-11-05 |
| 9 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.39% | $5.1M | $1.3B | 2026-11-06 |
| 10 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $4.1M | — | 2026-09-30 |
| 11 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.23% | $3.7M | $1.7B | 2026-11-06 |
| 12 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.04% | $3.3M | — | 2026-11-05 |
| 13 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.27% | $3.2M | $1.2B | 2026-11-06 |
| 14 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 0.90% | $3.2M | $346.3M | 2026-11-06 |
| 15 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.19% | $2.9M | — | 2026-08-31 |
| 16 | CANC Tema Oncology ETF | Nport | 1.31% | $2.8M | — | 2026-08-31 |
| 17 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $2.5M | — | 2026-11-05 |
| 18 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.18% | $2.5M | $1.4B | 2026-11-06 |
| 19 | PTH Invesco Dorsey Wright Healthcare Momentum ETF | Nport | 1.06% | $2.5M | — | 2026-07-31 |
| 20 | BBP Virtus Biotech Etf | Nport | 1.77% | $1.7M | — | 2026-07-31 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.6M | $93.2B | 2026-11-06 |
| 22 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.09% | $1.5M | — | 2026-09-30 |
| 23 | NUSC Nuveen ESG Small-Cap ETF | Nport | 0.12% | $1.5M | — | 2026-07-31 |
| 24 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $1.4M | — | 2026-11-05 |
| 25 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.05% | $1.4M | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.40
TTM Revenue
$201.73M
TTM Net Income
$-135.93M
TTM Op. Cash Flow
$-106.19M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $44.95M | $-41.90M | $-0.12 | $-38.56M |
| Q2 '26 | 2026-06-30 | $31.69M | $-62.84M | $-0.18 | $-42.97M |
| Q1 '26 | 2026-03-31 | $83.23M | $5.40M | $0.01 | $5.07M |
| Q4 '25 | 2025-12-31 | $41.87M | $-36.59M | $-0.11 | $-29.73M |
| Q3 '25 | 2025-09-30 | $13.12M | $-55.79M | $-0.16 | $-52.89M |
| Q2 '25 | 2025-06-30 | $4.83M | $-59.01M | $-0.17 | $-48.18M |
| Q1 '25 | 2025-03-31 | $3.08M | $-53.24M | $-0.16 | $-42.63M |
| Q4 '24 | 2024-12-31 | $5.71M | $-49.45M | $0.00 | $-46.30M |
| Q3 '24 | 2024-09-30 | $727.00K | $-41.21M | $-0.15 | $-31.09M |
| Q2 '24 | 2024-06-30 | $1.44M | $-462.49M | $-1.89 | $-37.32M |
| Q1 '24 | 2024-03-31 | — | $-14.79M | $-0.07 | $-15.70M |
| Q4 '23 | 2023-12-31 | — | $-13.79M | $-0.07 | $-15.03M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
6.08
P/S
9.08
EV/EBITDA
—
EV/Sales
8.98
ROE
-59.0%
ROA
-20.1%
Div Yield
0.00%
FCF Yield
-7.81%
Debt/Equity
0.96
Current Ratio
—
Market Cap
$1.54B
as of 2026-11-09
NUVB vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| JNJ Johnson & Johnson | $664.9B | 42.9 | +7.8% | +36.2% | 58 |
| MRK Merck & Co., Inc. | $361.7B | 153.3 | +4.9% | +39.7% | 45 |
| BMY Bristol-Myers Squibb Co. | $127.0B | 13.8 | +3.1% | +17.1% | 38 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +804.0% | 51 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +151.5% | 66 |
| GMAB Genmab A/S ADS | $33.0B | — | — | +73.4% | 20 |
| EXEL Exelixis Inc | $17.0B | 21.5 | +9.1% | +64.5% | 39 |
| NUVB Nuvation Bio Inc. | $1.5B | — | +654.2% | −49.0% | 24 |
| Peer median | $114.3B | 42.9 | +6.3% | +52.1% | 42 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
63.22M
SI % of Float
23.95%
Days to Cover
9.66
Short Vol Ratio
39.4%
Free Float
264.01M
Float %
75.2%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14